Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Sees Significant Decline in Short Interest

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the recipient of a significant decrease in short interest in May. As of May 15th, there was short interest totaling 6,757 shares, a decrease of 68.5% from the April 30th total of 21,481 shares. Based on an average trading volume of 32,441 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.7% of the shares of the company are sold short.

Hedge Funds Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics at the end of the most recent reporting period. Hedge funds and other institutional investors own 18.47% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Bluejay Diagnostics Stock Performance

NASDAQ BJDX opened at $2.14 on Monday. The firm’s fifty day moving average price is $1.90 and its two-hundred day moving average price is $2.85. Bluejay Diagnostics has a 1 year low of $1.62 and a 1 year high of $16.68. The firm has a market capitalization of $2.20 million, a P/E ratio of -0.18 and a beta of 0.82.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.95) earnings per share (EPS) for the quarter.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.